Browse Plenary Sessions

There are seven plenary sessions, one each day, beginning on Saturday evening. Hear from more than 40 leading researchers presenting the latest advances in neuroscience.

SESSION TOPICS AND SPEAKERS

Hot Topics Plenary Session

Saturday, April 22, 2017
5:00 p.m. to 6:30 p.m.

This session features translational research related to clinical issues of importance. Four outstanding physician-scientists provide summaries of their recent research findings and describe the clinical implications of the results.


Moderator

Eric Klawiter, MD
Member, Science Committee

Lysosomal Proteins as a Therapeutic Target in Neurodegeneration

Dimitri Krainc, MD, PhD
Northwestern University, Chicago, IL
Lysosomal Proteins as a Therapeutic Target in Neurodegeneration

The Role of CNS-draining Lymphatics in Neurological Diseases

Jonathan Kipnis, PhD
University of Virginia, Charlottesville, VA
The Role of CNS-draining Lymphatics in Neurological Diseases

Antisense Oligonucleotide Treatment (ASO) and SMA: Results of Clinical Trials

Claudia A. Chiriboga, MD
Columbia University, New York, NY
Antisense Oligonucleotide Treatment (ASO) and SMA: Results of Clinical Trials

Population-based Comprehensive Epilepsy Care in Ontario, Canada: A Model Network

O. Carter Snead, III, MD, FAAN
Hospital for Sick Children, Toronto, ON, Canada
Population-based Comprehensive Epilepsy Care in Ontario, Canada: A Model Network
Presidential Plenary Session

Sunday, April 23, 2017
9:15 a.m. to 12:00 p.m.

This session features the AAN's premier lecture awards for clinically relevant research and a presentation by a leading lecturer. Top researchers speak on some of the most significant findings in neurology in 2017. Don't miss the final presentation from AAN President Terrence L. Cascino, MD, FAAN, before he passes the gavel to President-elect Ralph L. Sacco, MD, MS, FAHA, FAAN.  


Moderator

Natalia Sana Rost, MD, FAAN
Vice Chair, AAN Science Committee

Presidential Lecture

Terrence L. Cascino, MD, FAAN
Mayo Clinic, Rochester, MN
Burnout, Wellness, and the Future of Our Profession

Sidney Carter Award in Child Neurology

J. Helen Cross, PhD
UCL-Institute of Child Health, London, United Kingdom
Improving Outcomes in Childhood Epilepsy

H. Houston Merritt Lecture

Nancy J. Newman, MD, FAAN

Emory University School of Medicine, Atlanta, GA
Ophthalmoscopy in the 21st Century


Robert Wartenberg Lecture

Ronald C. Petersen, PhD, MD, FAAN
Mayo Clinic, Rochester, MN
How Early Can We Diagnose Alzheimer's Disease?

 

Contemporary Clinical Issues Plenary Session

Monday, April 24, 2017
9:15 a.m. to 11:30 a.m.

This session highlights issues most critical to practicing neurologists, including abstracts related to new therapeutic developments, clinical applications of basic and translational research, and innovative technical developments. Commentary and discussion follow each presentation.


Moderator

Natalia Sana Rost, MD, FAAN
Vice Chair, AAN Science Committee

Nusinersen in Infants Diagnosed with Spinal Muscular Atrophy (SMA): Study Design and Initial Interim Efficacy and Safety Findings from the Phase 3 International ENDEAR Study

Presenter: Nancy L. Kuntz, MD
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL
Discussant: Charlotte J. Sumner, MD
Johns Hopkins Medicine, Baltimore, MD

A Woman “Found Down”

Louise D. McCullough, MD, PhD
The University of Texas Health Science Center at Houston, Houston, TX

Resumption of Oral Anticoagulation After Intracerebral Hemorrhage Is Associated with Decreased Mortality and Favorable Functional Outcome

Presenter: Alessandro Biffi, MD
Massachusetts General Hospital, Boston, MA
Discussant: Daniel F. Hanley, MD, FAAN
Johns Hopkins Medicine, Baltimore, MD

The Era of Targeted Preventive Treatment for Migraine: CGRP Monoclonal Antibodies

Amaal J. Starling, MD
Mayo Clinic, Phoenix, AZ

High Drug Prices: The Elephant in the Clinic

Dennis N. Bourdette, MD, FAAN
Oregon Health & Science University, Portland, OR

Targeting Neuronal Activity-regulated Neuroligin-3 Secretion for Glioma Therapy

Presenter: Michelle Monje, MD, PhD
Stanford University, Stanford, CA
Discussant: Tracy T. Batchelor, MD, MPH
Massachusetts General Hospital, Boston, MA
Clinical Trials Plenary Session

Tuesday, April 25, 2017
9:15 a.m. to 11:30 a.m.

This session covers important clinical topics identified from other society meetings that affect patient care. The latest updates within several clinical trials conducted over the course of the last year will be presented.


Moderators

Natalia Sana Rost, MD, FAAN
Vice Chair, AAN Science Committee
Deborah Hall, MD, PhD, FAAN
Member, Science Committee
Petra Kaufmann, MD, FAAN
Member, Science Committee

Effect of Intensive Systolic Blood Pressure Lowering on Hematoma Expansion in Patients with Intracerebral Hemorrhage: Analysis of Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) II Trial

Joshua N. Goldstein, MD, PhD
Massachusetts General Hospital, Boston, MA

A 2-year Multidomain Intervention of Diet, Exercise, Cognitive Training, and Vascular Risk Monitoring Versus Control to Prevent Cognitive Decline in At-risk Elderly People (FINGER): A Randomized Controlled Trial

TBD

Longitudinal Effect of Eteplirsen Versus Historical Control on Ambulation in Duchenne Muscular Dystrophy

Jerry R. Mendell, MD, FAAN
The Research Institute at Nationwide Children's Hospital, Columbus, OH

AVXS-101 Phase 1 Gene Therapy Clinical Trial in SMA Type 1: Event Free Survival and Achievement of Developmental Milestones

Jerry R. Mendell, MD, FAAN
The Research Institute at Nationwide Children's Hospital, Columbus, OH

Kids Are Not Just Little Adults: The Childhood and Adolescent Migraine Prevention Trial (CHAMP)

Scott Powers, PhD
Cincinnati Children's Hospital, Cincinnati, OH

Cannabidiol (CBD) Reduces Convulsive Seizure Frequency

J. Helen Cross, PhD
UCL-Institute of Child Health, London, United Kingdom

Efficacy of Siponimod in Secondary Progressive Multiple Sclerosis: Results of the Phase 3 Study

Ludwig Kappos, MD
University Hospital Basel, Basel, Switzerland

MGTX: Results of the Multinational Thymectomy Trial in Non-thymomatous Myasthenia Gravis

Gil I. Wolfe, MD, FAAN
University at Buffalo, Buffalo, NY
Frontiers in Neuroscience Plenary Session

Wednesday, April 26, 2017
9:15 a.m. to 11:30 a.m.

This plenary session features basic and translational research related to clinical issues of importance. Six outstanding physician-scientists provide summaries of their recent research findings and describe the clinical implications of the results.


Moderator


Randolph S. Marshall, MD, FAAN

Member, Science Committee


Genome and Epigenome Editing for Gene Therapy and Cell Programming

Charles Gersbach, PhD

Duke Center for Genomic and Computational Biology, Durham, NC


Vesicle Communication in the Tumor-bearing Brain

Xandra O. Breakefield, PhD

Massachusetts General Hospital, Charlestown, MA


Axonopathies: What Next?

Mary Reilly, MD, FRCP, FRCPI

National Hospital for Neurology and Neurosurgery, London, United Kingdom


The Lives of a Gene: Diverse Roles in Diseases of Developing and Mature Brain

M. Elizabeth Ross, MD, PhD

Cornell Medical College, New York, NY


Epilepsy at the Cutting Edge: Using Novel Models for Therapeutic Advances

Amy Brooks-Kayal, MD, FAAN

Children's Hospital Colorado, Aurora, CO


The Promise of Immunotherapy for Neurodegenerative Disorders: Progress and Challenges

Eliezer Masliah, MD

National Institute on Aging, Bethesda, MD

Controversies in Neurology Plenary Session

Thursday, April 27, 2017
9:15 a.m. to 11:30 a.m.

This session features experts discussing the most current and controversial issues in neuroscience. It is set up as debate format in which two speakers argue one side of a single topic, followed by a rebuttal.


Moderators

Joseph Jankovic, MD, FAAN
Member, Science Committee
Aleksandar Videnovic, MD, MSc, FAAN
Member, Science Committee

Is Focused Ultrasound Better Than Deep Brain Stimulation?

Yes: Paul S. Fishman, MD, PhD
University of Maryland School of Medicine, Baltimore, MD
No: Michael S. Okun, MD, FAAN
University of Florida, Gainesville, FL

Should Disease-modifying Therapies Be Stopped in Progressive MS?

Yes: John Corboy, MD, FAAN
University of Colorado School of Medicine, Aurora, CO
No: Robert T. Naismith, MD
Washington University, St. Louis, MO

Does Removal of Amyloid Improve Cognition in Alzheimer's Disease?

Yes: Reisa A. Sperling, MD
Brigham and Women's Hospital, Boston, MA
No: George Perry, PhD
The University of Texas at San Antonio, San Antonio, TX
Neurology Year in Review Plenary Session

Friday, April 28, 2017
9:15 a.m. to 11:30 a.m.

This session will feature six speakers, each focusing on the latest research that has happened in the last year within a specific subspecialty topic.


Moderator

Shafali Jeste, MD
Member, Science Committee

Movement Disorders

Susan Fox, MD
Toronto Western Hospital, Toronto, ON, Canada

Multiple Sclerosis

Peter A. Calabresi, MD, FAAN
Johns Hopkins University, Baltimore, MD

Pediatric Neurology

Erika Fullwood Augustine, MD, FAAN
University of Rochester Medical Center, Rochester, NY

Neurocritical Care

Paul Vespa, MD
University of California Los Angeles, Los Angeles, CA

Stroke

Brett M. Kissela, MD, MS, FAAN
University of Cincinnati Hospital, Cincinnati, OH

Epilepsy

Cynthia L. Harden, MD 
Mount Sinai Health System, New York, NY 

MEMBER LOG IN

Forgot password?

Advertisement
Advertisement